Chemomab Therapeutics Ltd (CMMB)
0.66
0.00 (0.00%)
USD |
NASDAQ |
Apr 23, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 9.375M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -59.26% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.73% |
Profile
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions. |
URL | https://www.chemomab.com |
Investor Relations URL | https://investors.chemomab.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | May. 31, 2024 (est.) |
Last Earnings Release | Mar. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions. |
URL | https://www.chemomab.com |
Investor Relations URL | https://investors.chemomab.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | May. 31, 2024 (est.) |
Last Earnings Release | Mar. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |